強皮症の診断と治療薬の世界市場レポート 2025年

強皮症の診断と治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.5％で、41億米ドルに成長します。予測期間中の成長は、精密医療の台頭、新規生物学的療法の開発、幹細胞研究の拡大、ドラッグデリバリーシステムの改善、希少疾病用医薬品の規制支援など、いくつかの要因によるものと考えられます。この期間の主な動向としては、AIを活用した診断アルゴリズム、遺伝子プロファイリングのための次世代シーケンシング、ナノテクノロジーを活用したドラッグデリバリー、リアルタイムモニタリングのためのウェアラブルバイオセンサー、組織再生のための3次元（3D）バイオプリンティングなどが挙げられます。

自己免疫疾患の有病率の増加は、強皮症の診断と治療薬市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が誤って身体自身の健康な細胞を攻撃することで発生します。自己免疫疾患の有病率は、遺伝的素因により増加傾向にあります。特定の遺伝的変異が免疫系の活動に影響を与え、結合組織の異常を引き起こすからです。強皮症の診断と治療薬は、早期発見を可能にし、臨床的意思決定を合理化する個別化治療戦略を促進することにより、自己免疫疾患管理を改善し、最終的に患者の転帰と生活の質を向上させる。例えば、2024年6月、オーストラリア保健福祉研究所（Australian Institute of Health and Welfare）は、2022年に51万4,000人（2.0％）が関節リウマチに罹患していると報告しました。さらに、この疾患による死亡者は1,322人で、2022年の全死亡者の0.7％を占めました。これらの数字は、強皮症の診断と治療薬市場を牽引する疾病負担の増大を浮き彫りにしています。

強皮症の診断と治療薬市場の主要企業は、疾患管理を強化し患者の転帰を改善するために、完全ヒトCD19 CAR T細胞療法などの革新的治療の開発に注力しています。CD19 CAR T細胞療法は免疫療法の一形態であり、患者のT細胞がB細胞に見られるタンパク質であるCD19を標的とするキメラ抗原受容体（CAR）を発現するように遺伝子改変されます。2023年10月、米国を拠点とするバイオ医薬品会社カイバーナ・セラピューティクス社は、完全ヒトCD19 CAR T細胞療法であるKYV-101の新薬治験許可申請をFDAより受理されました。本治療法はびまん性皮膚全身性硬化症（強皮症）の治療を目的としており、KYSA-5試験では、疾患の進行に関与するB細胞を標的とすることで、自己免疫疾患の治療における安全性と有効性を評価します。この治療法は免疫系をリセットし、強皮症患者の予後を改善することを目的としています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界強皮症の診断と治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の強皮症の診断と治療薬市場：成長率分析
• 世界の強皮症の診断と治療薬市場の実績：規模と成長, 2019-2024
• 世界の強皮症の診断と治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界強皮症の診断と治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の強皮症の診断と治療薬市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 免疫抑制剤
• エンドセリン受容体拮抗薬
• カルシウムチャネル遮断薬
• ホスホジエステラーゼ5型（PDE-5）阻害剤
• キレート剤
• プロスタサイクリン類似体
• その他の薬物の種類
• 世界の強皮症の診断と治療薬市場診断検査の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 血液検査
• 画像技術
• 皮膚生検
• 肺機能検査
• 心電図と心エコー図
• 世界の強皮症の診断と治療薬市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身性強皮症
• 局所性強皮症
• 世界の強皮症の診断と治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• トピック
• 世界の強皮症の診断と治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断センター
• 民間研究所
• 政府研究所
• その他のエンドユーザー
• 世界の強皮症の診断と治療薬市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プレドニゾン
• メチルプレドニゾロン
• デキサメタゾン
• 世界の強皮症の診断と治療薬市場免疫抑制剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトトレキサート
• ミコフェノール酸モフェチル
• アザチオプリン
• シクロホスファミド
• 世界の強皮症の診断と治療薬市場エンドセリン受容体拮抗薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ボセンタン
• アンブリセンタン
• マシテンタン
• 世界の強皮症の診断と治療薬市場カルシウムチャネル遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニフェジピン
• アムロジピン
• ジルチアゼム
• 世界の強皮症の診断と治療薬市場ホスホジエステラーゼ5型阻害剤（PDE-5）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• シルデナフィル
• タダラフィル
• バルデナフィル
• 世界の強皮症の診断と治療薬市場キレート剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• D-ペニシラミン
• デフェロキサミン
• 世界の強皮症の診断と治療薬市場プロスタサイクリン類似体のタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• エポプロステノール
• イロプロスト
• トレプロスチニル
• 世界の強皮症の診断と治療薬市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リツキシマブ（モノクローナル抗体）
• アバタセプト（T細胞モジュレーター）
• トシリズマブ（IL-6阻害剤）

第7章 地域別・国別分析

• 世界の強皮症の診断と治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の強皮症の診断と治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 強皮症の診断と治療薬市場：競合情勢
• 強皮症の診断と治療薬市場：企業プロファイル
  • Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GSK plc
• Boehringer Ingelheim International GmbH
• Lupin Diagnostics Limited
• Galapagos NV
• Cumberland Pharmaceuticals Inc.
• Inventiva S.A.
• Redx Pharma plc
• Kadmon Holdings Inc.
• Certa Therapeutics Pty Ltd
• Corbus Pharmaceuticals Holdings Inc.
• Emerald Health Pharmaceuticals Inc.
• aTyr Pharma Inc.
• MediciNova Inc.
• MitogenDx Inc.
• arGentis Pharmaceuticals LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 強皮症の診断と治療薬市場2029：新たな機会を提供する国
• 強皮症の診断と治療薬市場2029：新たな機会を提供するセグメント
• 強皮症の診断と治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Scleroderma diagnostics and therapeutics encompass advanced testing methods and targeted treatments aimed at detecting and managing scleroderma, a chronic autoimmune disorder that causes the hardening and tightening of the skin and connective tissues. These methods are used to identify symptoms such as Raynaud's phenomenon, skin thickening, and involvement of internal organs.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main drug types for scleroderma diagnostics and therapeutics include corticosteroids, immunosuppressive agents, endothelin receptor antagonists, calcium channel blockers, phosphodiesterase type 5 (PDE-5) inhibitors, chelating agents, prostacyclin analogues, and others. Corticosteroids are steroid hormones that help reduce inflammation and suppress the immune system. Diagnostic tests for scleroderma include blood tests, imaging techniques, skin biopsies, pulmonary function tests, electrocardiograms, and echocardiograms, which are categorized into systemic scleroderma and localized scleroderma based on their indications. These treatments and tests are administered via various routes, such as oral, injectable, and topical, and are used by a range of end-users, including hospitals, diagnostic centers, private laboratories, government laboratories, and others.

The scleroderma diagnostics and therapeutics market research report is one of a series of new reports from The Business Research Company that provides scleroderma diagnostics and therapeutics market statistics, including scleroderma diagnostics and therapeutics industry global market size, regional shares, competitors with a scleroderma diagnostics and therapeutics market share, detailed scleroderma diagnostics and therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the scleroderma diagnostics and therapeutics industry. This scleroderma diagnostics and therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The scleroderma diagnostics and therapeutics market size has grown strongly in recent years. It will grow from$2.71 billion in 2024 to $2.95 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to several factors, including the discovery of antinuclear antibodies, the introduction of pulmonary function tests, increased awareness of autoimmune diseases, the establishment of funding programs for rare diseases, and the expansion of clinical trial networks.

The scleroderma diagnostics and therapeutics market size is expected to see strong growth in the next few years. It will grow to$4.10 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth during the forecast period can be attributed to several factors, including the rise of precision medicine, the development of novel biologic therapies, the expansion of stem cell research, improved drug delivery systems, and regulatory support for orphan drugs. Key trends during this period include AI-powered diagnostic algorithms, next-generation sequencing for genetic profiling, nanotechnology-based drug delivery, wearable biosensors for real-time monitoring, and three-dimensional (3D) bioprinting for tissue regeneration.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the scleroderma diagnostics and therapeutics market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own healthy cells. The prevalence of autoimmune diseases is on the rise due to genetic predisposition, as certain genetic variations influence immune system activity and cause abnormalities in connective tissues. Scleroderma diagnostics and therapeutics help improve autoimmune disease management by enabling early detection and facilitating personalized treatment strategies that streamline clinical decision-making, ultimately improving patient outcomes and quality of life. For instance, in June 2024, the Australian Institute of Health and Welfare reported that 514,000 (2.0%) people were living with rheumatoid arthritis in 2022, which contributed to 2.0% of the total disease burden. Additionally, there were 1,322 deaths from the condition, accounting for 0.7% of all deaths in 2022. These figures highlight the growing disease burden, propelling the market for scleroderma diagnostics and therapeutics.

Leading companies in the scleroderma diagnostics and therapeutics market are focusing on developing innovative treatments, such as fully human CD19 CAR T-cell therapy, to enhance disease management and improve patient outcomes. CD19 CAR T-cell therapy is a form of immunotherapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor (CAR) targeting CD19, a protein found on B cells. In October 2023, Kyverna Therapeutics Inc., a U.S.-based biopharmaceutical company, received FDA clearance for its Investigational New Drug (IND) application for KYV-101, a fully human CD19 CAR T-cell therapy. The therapy is designed for the treatment of diffuse cutaneous systemic sclerosis (scleroderma), and the KYSA-5 trial will assess its safety and efficacy in treating autoimmune diseases by targeting B cells involved in disease progression. This therapy aims to reset the immune system and enhance patient outcomes in scleroderma.

In October 2023, Amgen Inc., a U.S.-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen seeks to strengthen its portfolio in rare autoimmune and inflammatory diseases by leveraging Horizon Therapeutics' expertise and innovative drug pipeline. Horizon Therapeutics, an Ireland-based biotechnology company, specializes in developing treatments for scleroderma, focusing on innovative therapies that target fibrosis and regulate the immune system.

Major players in the scleroderma diagnostics and therapeutics market are Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., GSK plc, Boehringer Ingelheim International GmbH, Lupin Diagnostics Limited, Galapagos NV, Cumberland Pharmaceuticals Inc., Inventiva S.A., Redx Pharma plc, Kadmon Holdings Inc., Certa Therapeutics Pty Ltd, Corbus Pharmaceuticals Holdings Inc., Emerald Health Pharmaceuticals Inc., aTyr Pharma Inc., MediciNova Inc., MitogenDx Inc., and arGentis Pharmaceuticals LLC.

North America was the largest region in the scleroderma diagnostics and therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in scleroderma diagnostics and therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the scleroderma diagnostics and therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The scleroderma diagnostics and therapeutics market includes revenues earned by entities by providing services such as advanced diagnostic imaging and laboratory testing, biomarker and genetic testing, targeted therapeutic development, personalized treatment planning, and remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Scleroderma Diagnostics And Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on scleroderma diagnostics and therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for scleroderma diagnostics and therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The scleroderma diagnostics and therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Corticosteroids; Immunosuppressive Agents; Endothelin Receptor Antagonists; Calcium Channel Blockers; Phosphodiesterase Type 5 (PDE-5) Inhibitors; Chelating Agents; Prostacyclin Analogues; Other Drug Types
• 2) By Diagnostic Test Type: Blood Tests; Imaging Techniques; Skin Biopsy; Pulmonary Function Tests; Electrocardiogram And Echocardiogram
• 3) By Indication: Systemic Scleroderma; Localized Scleroderma
• 4) By Route Of Administration: Oral; Injectable; Topical
• 5) By End-User: Hospitals; Diagnostic Centers; Private Laboratories; Government Laboratories; Other End-Users
• Subsegments:
• 1) By Corticosteroids: Prednisone; Methylprednisolone; Dexamethasone
• 2) By Immunosuppressive Agents: Methotrexate; Mycophenolate Mofetil; Azathioprine; Cyclophosphamide
• 3) By Endothelin Receptor Antagonists: Bosentan; Ambrisentan; Macitentan
• 4) By Calcium Channel Blockers: Nifedipine; Amlodipine; Diltiazem
• 5) By Phosphodiesterase Type 5 Inhibitors (Pde-5) Inhibitors: Sildenafil; Tadalafil; Vardenafil
• 6) By Chelating Agents: D-Penicillamine; Deferoxamine
• 7) By Prostacyclin Analogues: Epoprostenol; Iloprost; Treprostinil
• 8) By Other Drug Types: Rituximab (Monoclonal Antibody); Abatacept (T-Cell Modulator); Tocilizumab (Il-6 Inhibitor)
• Companies Mentioned: Johnson and Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Scleroderma Diagnostics And Therapeutics Market Characteristics

3. Scleroderma Diagnostics And Therapeutics Market Trends And Strategies

4. Scleroderma Diagnostics And Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Scleroderma Diagnostics And Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Scleroderma Diagnostics And Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Scleroderma Diagnostics And Therapeutics Market Growth Rate Analysis
• 5.4. Global Scleroderma Diagnostics And Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Scleroderma Diagnostics And Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Scleroderma Diagnostics And Therapeutics Total Addressable Market (TAM)

6. Scleroderma Diagnostics And Therapeutics Market Segmentation

• 6.1. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressive Agents
• Endothelin Receptor Antagonists
• Calcium Channel Blockers
• Phosphodiesterase Type 5 (PDE-5) Inhibitors
• Chelating Agents
• Prostacyclin Analogues
• Other Drug Types
• 6.2. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Blood Tests
• Imaging Techniques
• Skin Biopsy
• Pulmonary Function Tests
• Electrocardiogram And Echocardiogram
• 6.3. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Scleroderma
• Localized Scleroderma
• 6.4. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• 6.5. Global Scleroderma Diagnostics And Therapeutics Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Centers
• Private Laboratories
• Government Laboratories
• Other End-Users
• 6.6. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prednisone
• Methylprednisolone
• Dexamethasone
• 6.7. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Immunosuppressive Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Methotrexate
• Mycophenolate Mofetil
• Azathioprine
• Cyclophosphamide
• 6.8. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Endothelin Receptor Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bosentan
• Ambrisentan
• Macitentan
• 6.9. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nifedipine
• Amlodipine
• Diltiazem
• 6.10. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Phosphodiesterase Type 5 Inhibitors (PDE-5) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sildenafil
• Tadalafil
• Vardenafil
• 6.11. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Chelating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• D-Penicillamine
• Deferoxamine
• 6.12. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Prostacyclin Analogues, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epoprostenol
• Iloprost
• Treprostinil
• 6.13. Global Scleroderma Diagnostics And Therapeutics Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rituximab (Monoclonal Antibody)
• Abatacept (T-Cell Modulator)
• Tocilizumab (IL-6 Inhibitor)

7. Scleroderma Diagnostics And Therapeutics Market Regional And Country Analysis

• 7.1. Global Scleroderma Diagnostics And Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Scleroderma Diagnostics And Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market

• 8.1. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Scleroderma Diagnostics And Therapeutics Market

• 9.1. China Scleroderma Diagnostics And Therapeutics Market Overview
• 9.2. China Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Scleroderma Diagnostics And Therapeutics Market

• 10.1. India Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Scleroderma Diagnostics And Therapeutics Market

• 11.1. Japan Scleroderma Diagnostics And Therapeutics Market Overview
• 11.2. Japan Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Scleroderma Diagnostics And Therapeutics Market

• 12.1. Australia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Scleroderma Diagnostics And Therapeutics Market

• 13.1. Indonesia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Scleroderma Diagnostics And Therapeutics Market

• 14.1. South Korea Scleroderma Diagnostics And Therapeutics Market Overview
• 14.2. South Korea Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Scleroderma Diagnostics And Therapeutics Market

• 15.1. Western Europe Scleroderma Diagnostics And Therapeutics Market Overview
• 15.2. Western Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Scleroderma Diagnostics And Therapeutics Market

• 16.1. UK Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Scleroderma Diagnostics And Therapeutics Market

• 17.1. Germany Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Scleroderma Diagnostics And Therapeutics Market

• 18.1. France Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Scleroderma Diagnostics And Therapeutics Market

• 19.1. Italy Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Scleroderma Diagnostics And Therapeutics Market

• 20.1. Spain Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Scleroderma Diagnostics And Therapeutics Market

• 21.1. Eastern Europe Scleroderma Diagnostics And Therapeutics Market Overview
• 21.2. Eastern Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Scleroderma Diagnostics And Therapeutics Market

• 22.1. Russia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Scleroderma Diagnostics And Therapeutics Market

• 23.1. North America Scleroderma Diagnostics And Therapeutics Market Overview
• 23.2. North America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Scleroderma Diagnostics And Therapeutics Market

• 24.1. USA Scleroderma Diagnostics And Therapeutics Market Overview
• 24.2. USA Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Scleroderma Diagnostics And Therapeutics Market

• 25.1. Canada Scleroderma Diagnostics And Therapeutics Market Overview
• 25.2. Canada Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Scleroderma Diagnostics And Therapeutics Market

• 26.1. South America Scleroderma Diagnostics And Therapeutics Market Overview
• 26.2. South America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Scleroderma Diagnostics And Therapeutics Market

• 27.1. Brazil Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Scleroderma Diagnostics And Therapeutics Market

• 28.1. Middle East Scleroderma Diagnostics And Therapeutics Market Overview
• 28.2. Middle East Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Scleroderma Diagnostics And Therapeutics Market

• 29.1. Africa Scleroderma Diagnostics And Therapeutics Market Overview
• 29.2. Africa Scleroderma Diagnostics And Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Scleroderma Diagnostics And Therapeutics Market, Segmentation By Diagnostic Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Scleroderma Diagnostics And Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Scleroderma Diagnostics And Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Scleroderma Diagnostics And Therapeutics Market Competitive Landscape
• 30.2. Scleroderma Diagnostics And Therapeutics Market Company Profiles
  • 30.2.1. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Scleroderma Diagnostics And Therapeutics Market Other Major And Innovative Companies

• 31.1. GSK plc
• 31.2. Boehringer Ingelheim International GmbH
• 31.3. Lupin Diagnostics Limited
• 31.4. Galapagos NV
• 31.5. Cumberland Pharmaceuticals Inc.
• 31.6. Inventiva S.A.
• 31.7. Redx Pharma plc
• 31.8. Kadmon Holdings Inc.
• 31.9. Certa Therapeutics Pty Ltd
• 31.10. Corbus Pharmaceuticals Holdings Inc.
• 31.11. Emerald Health Pharmaceuticals Inc.
• 31.12. aTyr Pharma Inc.
• 31.13. MediciNova Inc.
• 31.14. MitogenDx Inc.
• 31.15. arGentis Pharmaceuticals LLC

32. Global Scleroderma Diagnostics And Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Scleroderma Diagnostics And Therapeutics Market

34. Recent Developments In The Scleroderma Diagnostics And Therapeutics Market

35. Scleroderma Diagnostics And Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Scleroderma Diagnostics And Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Scleroderma Diagnostics And Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Scleroderma Diagnostics And Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34961_Scleroderma_Diagnostics_And_Therapeutics_GMR_2025